Literature DB >> 32030289

Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited.

Chan Yeu Pu1, Sai Yendamuri2,3.   

Abstract

Entities:  

Year:  2019        PMID: 32030289      PMCID: PMC6987996          DOI: 10.21037/jtd.2019.11.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  CALGB 9633: an underpowered trial with a methodologically questionable conclusion.

Authors:  Artur Katz; Everardo D Saad
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

2.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 3.  Adjuvant or neoadjuvant chemotherapy for NSCLC.

Authors:  Philip McElnay; Eric Lim
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

4.  Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.

Authors:  Whitney S Brandt; Wanpu Yan; Jian Zhou; Kay See Tan; Joseph Montecalvo; Bernard J Park; Prasad S Adusumilli; James Huang; Matthew J Bott; Valerie W Rusch; Daniela Molena; William D Travis; Mark G Kris; Jamie E Chaft; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-10       Impact factor: 5.209

Review 5.  Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Authors:  Matthew D Hellmann; Jamie E Chaft; William N William; Valerie Rusch; Katherine M W Pisters; Neda Kalhor; Apar Pataer; William D Travis; Stephen G Swisher; Mark G Kris
Journal:  Lancet Oncol       Date:  2014-01       Impact factor: 41.316

6.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

7.  Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer.

Authors:  Meng Wang; Jing Zhao; Yan-Jun Su; Xiao-Liang Zhao; Chang-Li Wang
Journal:  Oncol Lett       Date:  2012-09-03       Impact factor: 2.967

Review 8.  Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

Authors:  Eric Lim; Grace Harris; Amit Patel; Iki Adachi; Lyn Edmonds; Fujian Song
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

9.  A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

Authors:  Virginie Westeel; Elisabeth Quoix; Marc Puyraveau; A Lavolé; Denis Braun; Silvy Laporte; Laurence Bigay-Game; Jean-Louis Pujol; Gervais Ozenne; Alain Rivière; Jean-Yves Douillard; Bernard Lebeau; Didier Debieuvre; Michel Poudenx; Philippe David; Olivier Molinier; Gérard Zalcman; Etienne Lemarié; Franck Morin; Alain Depierre; Bernard Milleron
Journal:  Eur J Cancer       Date:  2013-06-01       Impact factor: 9.162

Review 10.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Authors: 
Journal:  Lancet       Date:  2014-02-25       Impact factor: 79.321

View more
  1 in total

1.  Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer.

Authors:  Ke Xu; Haitang Yang; Wenyan Ma; Liwen Fan; Beibei Sun; Zhexin Wang; Mohammad Faisal Al-Hurani; Ralph A Schmid; Feng Yao
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.